Clinical Trials
28 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07416188 2026-05-27
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT07302347 2026-05-26
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05674825 2026-05-22
MCW I-PREDICT
Medical College of Wisconsin
Phase 1/2 Recruiting
NCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT06796907 2026-05-22
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT07407582 2026-05-20
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
Phase 1/2 Recruiting
NCT04901702 2026-05-19
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05468359 2026-05-19
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT04742101 2026-05-18
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Servier
Phase 1/2 Completed
NCT05123482 2026-05-18
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
Phase 1/2 Recruiting
NCT02130492 2026-05-15
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)
Weill Medical College of Cornell University
Phase 1/2 Suspended
NCT07339176 2026-05-14
OP-NEU-101
Onchilles Pharma Inc
Phase 1/2 Recruiting
NCT03686124 2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06941272 2026-05-12
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06634589 2026-05-11
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
Phase 1/2 Recruiting
NCT02908906 2026-05-08
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT03382977 2026-05-08
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
Phase 1/2 Terminated
NCT06380816 2026-05-08
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Phase 1/2 Recruiting
NCT06678659 2026-05-08
DAHLIA
Recursion Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT06818643 2026-05-08
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07529808 2026-05-08
ChefHat-001
BigHat Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT06993844 2026-05-06
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Phase 1/2 Recruiting
NCT05394337 2026-05-05
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07567469 2026-05-05
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Regeneron Pharmaceuticals
Phase 1/2 Not yet recruiting
NCT05933265 2026-05-04
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Phase 1/2 Active not recruiting